Granted Patent
B2
US 12,714,750 · App. 17/820,724 · Granted Aug 25, 2026
Compositions and methods for treating cancer with anti-CD33 immunotherapy
View Patent ↗
Loading inventors, assignments & file history…
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 9, 2022
From: DIMITROV, DIMITER S.; ZHU, ZHONGYU
To: THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061708/0811 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 9, 2022
From: ORENTAS, RIMAS J.; SCHNEIDER, DINA; DROPULIC, BORO
To: LENTIGEN TECHNOLOGY, INC.
Reel/Frame 061708/0465 →
Continuity (5)
Provisional Application
62620139
· Jan 22, 2018
Provisional Application
62476438
· Mar 24, 2017
References Cited (57)
US 20140186365A1
· Robinson
· 2014
[cited by applicant]
US 20220281946A1
· Orentas
· 2022
[cited by examiner]
US 20240025962A1
· Orentas
· 2024
[cited by examiner]
US 20240043497A1
· Orentas
· 2024
[cited by examiner]
CN 104877032
· 2015
[cited by applicant]
CN 105820255
· 2016
[cited by applicant]
CN 109843922
· 2019
[cited by applicant]
EP 2332994
· 2011
[cited by applicant]
WO WO2008143702
· 2008
[cited by applicant]
WO WO2008143702A2
· 2008
[cited by examiner]
WO WO2012079000
· 2012
[cited by applicant]
WO WO2014052064
· 2014
[cited by applicant]
WO WO2014052064A1
· 2014
[cited by examiner]
WO WO2014065961A1
· 2014
[cited by examiner]
WO WO2015150526
· 2015
[cited by applicant]
WO WO2016014576
· 2016
[cited by applicant]
WO WO2016014789A2
· 2016
[cited by examiner]
WO WO2016174408
· 2016
[cited by applicant]
WO WO2016174461
· 2016
[cited by applicant]
WO WO2016201394
· 2016
[cited by applicant]
WO WO2017075399
· 2017
[cited by applicant]
WO WO2017075399A1
· 2017
[cited by examiner]
WO WO2018045325
· 2018
[cited by applicant]
Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomark Res. Jun. 24, 2017;5:22. doi: 10.1186/s40364-017-0102-y. PMID: 28652918; PMCID: PMC5482931 (Year: 2017).
[cited by examiner]
Alabanza, L., et al., 2017. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Molecular Therapy, 25(11), pp. 2452-2465 (Year: 2017).
[cited by examiner]
NCT01864902 “Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33” published Jan. 28, 2016 (Year: 2016).
[cited by examiner]
Uniprot P01732: CD8A_HUMAN (Year: 2025).
[cited by examiner]
Mazinani M et al. CAR-T cell potency: from structural elements to vector backbone components. Biomarker Research 2022 10, Article No. 70 1-24 (Year: 2022).
[cited by examiner]
Porembka, M.R., Mitchem, J.B., Belt, B.A. et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother 61, 1373-1385…
[cited by examiner]
Human Protein Atlas: Expression of CD33 in cancer, accessed by the examiner Dec. 2025 (Year: 2025).
[cited by examiner]
Fultang, Livingstone, et al. “MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers.” EBio Medicine 47 (2019): 235-246. (Year: 2019).
[cited by examiner]
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerances to Amino Acid Substitutions,” Science, 1990, 247:1306-1310.
[cited by applicant]
Ceppi et al., “Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma,” Transfusion, 2018, 58:1414-1420.
[cited by applicant]
Eck et al., Goodman and Gilman's, McGraw-Hill, Health Profession Division, 1996, pp. 77-101.
[cited by applicant]
Fromm et al., “Flow cytometric analysis of CD123 is useful for immunophenotyping classical Hodgkin lymphoma,” Cytometry Part B, 2011, 808:91-99.
[cited by applicant]
Gill et al., “Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells,” Blood, 2014, 123(15):2343-2354.
[cited by applicant]
International Search Report and Written Opinion issued in PCT/US2018/024183, mailed Jun. 7, 2018, 14 pages.
[cited by applicant]
Kean et al., “Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis, ” Blood, 2018, 131(24):23630-2639.
[cited by applicant]
Kenderian et al., “CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia,” Leukemia, Aug. 2015, 29(8):1637, 40 pages.
[cited by applicant]
Kim et al., “Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia,” Cell, 2018, 173:1439-1453.
[cited by applicant]
Mardiros et al., “T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and anti-tumor effects against human acute myeloid leukemia,” Blood, 2013, 122(18):3138-3148.
[cited by applicant]
Ngo et al., “Computational complexity, protein structure prediction, and the levinthal paradox,” in The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., eds., Birkhauser Boston: Boston, MA, 1994, …
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2018/024183, dated Oct. 3, 2019, 9 pages.
[cited by applicant]
Pizzitola et al., “Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo, ” Leukemia, 2014 28:1596-1605.
[cited by applicant]
Tettamanti et al., “Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor,” British Journal of Haematology, 2013, 161:389-401.
[cited by applicant]
Voskoglou-Nomikos et al., “Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models,” Clinical Cancer.
[cited by applicant]
Wang et al., “Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia,” Molecular Therapy, 2015, 23(1):184-191.
[cited by applicant]
Yan et al., “Two-Amino Acid Molecular Switch in an Epithelial Morphogen That Regulates Binding to Two Distinct Receptors,” Science, 2000, 290:523-527.
[cited by applicant]